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Context: Pheochromocytomas can usually be confirmed or excluded using currently available bio-
chemical tests of catecholamine excess. Follow-up tests are, nevertheless, often required to dis-
tinguish false-positive fromtrue-positive results. Theglucagonstimulation test representsone such
test; its diagnostic utility is, however, unclear.
Objective: The aim of the study was to determine the diagnostic power of the glucagon test to
exclude or confirm pheochromocytoma.
Design, Setting, and Subjects: Glucagon stimulation tests were carried out at three specialist
referral centers in 64 patients with pheochromocytoma, 38 patients in whom the tumor was
excluded, and in a reference group of 36 healthy volunteers.
Main Outcome Measures: Plasma concentrations of norepinephrine and epinephrine were mea-
sured before and after glucagon administration. Several absolute and relative test criteria were
used for calculating diagnostic sensitivity and specificity. Expression of the glucagon receptor was
examined in pheochromocytoma tumor tissue from a subset of patients.
Results: Larger than 3-fold increases in plasma norepinephrine after glucagon strongly predicted
the presence of a pheochromocytoma (100% specificity and positive predictive value). However,
irrespective of the various criteria examined, glucagon-provoked increases in plasma cat-
echolamines revealed the presence of the tumor in less than 50% of affected patients. Diagnostic
sensitivity was particularly low in patients with pheochromocytomas due to von Hippel-Lindau
syndrome. Tumors from these patients showedno significant expression of the glucagon receptor.
Conclusion: The glucagon stimulation test offers insufficient diagnostic sensitivity for reliable
exclusion or confirmation of pheochromocytoma. Because of this and the risk of hypertensive
complications, the test should be abandoned in routine clinical practice. (J Clin Endocrinol Metab
95: 238–245, 2010)
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Pheochromocytomas and paragangliomas are tumorsof chromaffin cells that must be considered in many
patientswith hypertension aswell as others inwhom there
is suspicion of the tumor due to presence of an adrenal
incidentaloma or an underlying hereditary predisposition
(1). Becauseof the significant risksof excessmorbidity and
mortality, definitive exclusion or confirmation of these
tumors is an important concern. Diagnosis in most cases
is now relatively easy due to the introduction of new bio-
chemical tests. Measurements of plasma free metaneph-
rines, in particular, offer diagnostic sensitivity of more
than 97% (2–5). Diagnostic specificity is, however, lim-
ited. False-positive test results—mainly due to inappro-
priate sampling conditions, confounding influences of
medications, and clinical conditions associated with ele-
vated sympathetic activity—remain a problem (1). Fol-
low-up tests are therefore often required to distinguish
true- from false-positive results. The glucagon stimulation
test is one potential test for this purpose (6).
Use of the glucagon test to establish a positive result
depends on demonstration of a large increment in plasma
concentrations of norepinephrine within 3 min of an iv
bolus injection of glucagon. Lack of response character-
izes negative test results in patients without pheochromo-
cytoma. The test, however, is fraught with numerous
methodological problems. In particular, the criteria for
establishing positive and negative test results from re-
sponses of both norepinephrine and epinephrine have not
been adequately defined and tested. For this, the nature of
responses of both catecholamines should ideally be estab-
lished in a reference population, and then tested to estab-
lish respective diagnostic sensitivities and specificities in
patients with and without the tumor. To date, such an
approach has not been used; additionally, the populations
of patients studied have been relatively small (7–11).
Therefore, it remains unclear how useful the glucagon test
is in clinical practice.
In the present study,we examined the responses of both
plasma norepinephrine and epinephrine to glucagon in a
reference population of healthy volunteers. We then es-
tablished diagnostic power of the test in groups of patients
with confirmed pheochromocytoma compared with pa-
tients in whom the tumor was excluded by a combination
of negative follow-up and imaging studies.
Subjects and Methods
Subjects
All patients were tested at the National Institutes of Health
(NIH, Bethesda, MD), Radboud University Nijmegen Medical
Center (Nijmegen, The Netherlands), or the University of Flo-
rence (Florence, Italy). A diagnosis of pheochromocytoma was
confirmed in 64 patients (30 females, 34males), aged 36 14 yr
(mean  SD), based on histological examination of surgically
resected tumor specimens. This group (tumor-confirmed group)
included 26 patients with an apparent sporadic pheochromocy-
toma, 23 patients with von Hippel-Lindau (VHL) syndrome, 14
patients withmultiple endocrine neoplasia type 2 (MEN-2), and
one patient with neurofibromatosis type 1.
A group of 38 patients (23 females, 15males), aged 44 9 yr,
with suspected pheochromocytoma inwhom the tumorwas sub-
sequently excluded, served to establish diagnostic specificity.
Pheochromocytomawas excluded in this group (tumor excluded
group) by one ormore of the following criteria: negative imaging
studies; pathological examination of a surgically resected adre-
nal mass; and normal biochemical test results with lack of the
tumor on patient follow-up 2 yr or more after initial testing.
A third groupof 36 subjects (19 females, 17males), aged41
13 yr, consisting of 31 healthy normotensive volunteers and five
patients with primary hypertension served to establish the ref-
erence values for plasma catecholamine responses to glucagon
(reference group).
Written informed consentwasobtained fromall patientswho
were examined at the NIH. In the other centers (Nijmegen, The
Netherlands; and Florence, Italy), glucagon tests were carried
out in patients under regular clinical care conditions, and the
ethical committee approved the use of those data for scientific
purposes. The protocol for glucagon tests in healthy subjects
(Florence, Italy) was approved by the local ethics committee.
Glucagon provocation testing
Glucagon tests were carried out after an overnight fast. A
baseline blood sample was initially taken through a forearm ve-
nous cannula after 20 min of supine rest. One milligram of glu-
cagon was then administered iv. A second blood sample was
drawn between 2 and 3 min after glucagon administration. In a
subset of patients (seven patients with pheochromocytoma, 35
patients without pheochromocytoma, and 14 subjects of the ref-
erence group), the time course of plasma norepinephrine and
plasma epinephrine responses to glucagonwas determined using
blood samples collected at 1, 2, 3, and 5 min after glucagon.
Blood pressure was monitored throughout testing.
Biochemical assays
Plasma concentrations of catecholamines before and after
glucagonwere determined usingHPLCwith electrochemical de-
tection, as described previously (12). The samples of the subjects
from Florence were assayed by a radioenzymatic method. Base-
line plasma concentrations of free metanephrines were deter-
mined using a different HPLC with electrochemical detection
procedure (13).
Analysis of glucagon test results
For the subjects in whommultiple blood samples were taken
after glucagon, the peak responses of norepinephrine and epi-
nephrine were defined as the highest plasma concentration of
each analyte during the first 3 min after glucagon. For all other
patients, the peak response was determined from the sample
collected between 2 and 3 min after glucagon.
Four criteria were used to define a positive (i.e. abnormal) glu-
cagon test result. Three of the four criteria were based on the glu-
cagon-evoked responses of plasma catecholamines in the reference
group: 1) an increase in plasma concentrations of norepinephrine
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that exceeded the largest absolute increase in the referencegroup;2)
an increase in plasma norepinephrine and/or epinephrine that ex-
ceeded the respective largest absolute increase of analytes in the
reference group; and 3) a fold-increase in plasma concentrations of
norepinephrineabovebaseline levels that exceeded thehighest fold-
increase in the reference group. Additionally, the commonly used
definition of a larger than 3-fold increase in plasma concentrations
of norepinephrine abovebaseline levelswas examinedas the fourth
criterion of a positive test result (14).
Sensitivity, specificity, and positive and negative predictive
values for the different parameters were calculated as previously
described (2).
To establish the utility of the glucagon stimulation test as a
follow-up test, diagnostic sensitivity and specificity were also
examined in a subgroupof patientswhohad elevations inplasma
normetanephrine and metanephrine that were of insufficient
magnitude to unequivocally establish a positive diagnosis (i.e.
concentrations above the upper reference intervals, but not high
enough toprovide100%positive predictive value—about 4-fold
higher than the upper reference intervals). Another subanalysis
was carried out in patients with normal baseline plasma concen-
trations of both norepinephrine and epinephrine. Additionally,
separate analyses of diagnostic sensitivity were performed in
three subgroups of patients with pheochromocytoma, including
those with apparently sporadic tumors and those with tumors
associated with MEN-2 and VHL syndrome.
Expression of the glucagon receptor
TumorspecimensfromsevenpatientswithMEN-2and-11with
VHL syndrome were examined for expression of the glucagon re-
ceptor by quantitative PCR. In brief, RNAwas extracted from fro-
zen samples of tumor tissue and reversibly transcribed to cDNA
using random hexamers. Real-time quantitative PCR (TaqMan
PCR) with a 7000 Sequence Detector (Applied Biosystems, Foster
City,CA)wasused forquantificationof glucagon receptormRNA.
Glucagon receptor forwardprimer: 5-TGCACTGCACCCGCA
AT-3; glucagon receptor reverseprimer: 5-GCACGGAGCTGG
CTT TCA-3; glucagon receptor TaqMan probe: 5(FAM)-CGC
GAA TCT GTT TGC GTC CTT CG-(TAMRA)3.
Specimens from six patients with MEN-2 and -4 with VHL
syndrome were also examined for expression of the glucagon
receptor by immunohistochemistry. Primary antibodies for the
glucagon receptor (rabbit polyclonal antiglucagon receptor,
1:100) were from Novus Biologicals (Littleton, CO), and those
for tyrosine hydroxylase (mouse monoclonal antityrosine hy-
droxylase, 1:250) were from ImmunoStar, Inc. (Hudson, WI).
Complete details on the procedures for quantitative PCR and
immunohistochemstry can be obtained fromThanh-Truc Huynh
(E-mail: huynht@mail.nih.gov).
Statistical analyses
Baseline data for plasma concentrations of catecholamines
andmetanephrines are presented asmedian values and ranges.
Where appropriate, data were log-transformed before statis-
tical analysis. Differences between groups were compared by
ANOVA with Scheffe´’s test. Changes in plasma concentrations
of catecholamines after glucagon were examined using paired t
tests. A two-tailed P value of 0.05 was considered to be sta-
tistically significant.
Results
Baseline plasma concentrations of catecholamines
and metanephrines
Baseline plasma concentrations of norepinephrine or epi-
nephrine or both catecholamines were elevated in 49 of the
64 patients with pheochromocytoma, whereas plasma con-
centrations of normetanephrine or metanephrine or both
metaboliteswere elevated in 63patients. Patientswith pheo-
chromocytoma had 180 to 360% higher (P  0.0001)
median baseline plasma concentrations of norepinephrine
than those without pheochromocytoma (Table 1). Me-
dian baseline plasma concentrations of epinephrine were
60 to 90% higher in patients with pheochromocytoma
TABLE 1. Baseline and peak plasma concentrations of catecholamines after glucagon administration in the
reference group and groups of patients with confirmed and excluded pheochromocytoma
URI
(nmol/liter)
Baseline values
(nmol/liter)
Peak values
(nmol/liter)
Median Range Median Range
Reference group
Norepinephrine 2.90 1.17 0.58–9.24 1.45 0.66–8.19
Epinephrine 0.50 0.10 0.01–0.52 0.28 0.01–1.50
Normetanephrine 0.61 0.35 0.18–0.50
Metanephrine 0.31 0.10 0.04–0.21
Tumor excluded
Norepinephrine 2.90 1.96 0.59–6.15 2.59 0.72–7.50
Epinephrine 0.50 0.12 0.01–0.75 0.31 0.02–6.73
Normetanephrine 0.61 0.37 0.09–1.33
Metanephrine 0.31 0.17 0.03–0.63
Tumor confirmed
Norepinephrine 2.90 5.40 0.57–41.3 8.36 1.14–120.5
Epinephrine 0.50 0.19 0.02–6.9 0.61 0.03–30.9
Normetanephrine 0.61 2.66 0.28–173
Metanephrine 0.31 0.29 0.04–20
URI, Upper reference intervals are shown for baseline values of norepinephrine, epinephrine, normetanephrine, and metanephrine.
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than in subjectswithout the tumor, but this differenceonly
reached significance (P 0.016) for the comparison with
the reference group. The pheochromocytoma-associated
percentage elevations in median baseline plasma concen-
trations of normetanephrine and metanephrine were
larger (P  0.0001) than respective elevations of norepi-
nephrine and epinephrine. Median baseline plasma con-
centrations of normetanephrine in patients with pheo-
chromocytoma were 620 to 660% higher (P  0.0001)
than in subjects without the tumor (compared with only
180 to 360% for norepinephrine), whereas plasma con-
centrations ofmetanephrinewere 70 to 190%higher (P
0.0001) than in subjects without the tumor (compared
with 60 to 90% for epinephrine).
Effects of glucagon administration
In the subset of patients with pheochromocytoma (n
7) inwhom the time course of plasma catecholamine levels
after glucagon could be assessed, peak levels were reached
at 2min (data not shown). At 5min, plasma levels already
had decreased substantially, but not to baseline values.
Administration of glucagon resulted in significant (P
0.0001) increases in plasma concentrations of both nor-
epinephrine and epinephrine in all three groups of subjects
(Fig. 1). The increases were not consistent for all subjects
in any group. There was considerable overlap in peak
plasma concentrations of both norepinephrine and epi-
nephrine among all three groups. The degree of overlap in
peak plasma concentrations was larger for epinephrine
than for norepinephrine (Fig. 1).
Increases of plasma concentrations of norepinephrine,
expressed in terms of absolute increments, weremore pro-
nounced in patients with pheochromocytoma than in the
two groups of subjects without pheochromocytoma (Fig.
2). The median increment of plasma norepinephrine con-
centrations in patients with pheochromocytomawas 1.17
nmol/liter, compared with smaller increments of 0.42
nmol/liter in patients in whom the tumor was excluded
(P  0.0001) and 0.16 nmol/liter in the reference group
(P 0.0001). Nevertheless, there was considerable over-
lap of the absolute increments in plasma norepinephrine
concentrations among the three groups. Similarly, relative
increases in plasmanorepinephrine (i.e. fold or percentage
increases after glucagon relative to baseline values), also
showed considerable overlap, such thatwhen expressed in
FIG. 2. Dot plots showing changes in plasma concentrations of
norepinephrine (A and B) and of epinephrine (C and D) in individual
patients with and without pheochromocytoma, and in the reference
group. Absolute increments ( increases) in plasma concentrations of
norepinephrine and epinephrine after glucagon (plasma concentrations
after glucagon minus baseline plasma concentrations before glucagon)
are shown in panels A and C, respectively, whereas relative increments
(fold-increases) in plasma norepinephrine and epinephrine levels
after glucagon (peak plasma concentrations divided by baseline
concentrations) are shown in panels B and D, respectively. *, P  0.05;
***, P  0.0001 difference in responses of indicated groups.
FIG. 1. Line graphs showing plasma concentrations of norepinephrine
(A) and epinephrine (B) at baseline (BL) and after glucagon (Peak) in
individual patients with and without pheochromocytoma, and in the
reference group. ***, P  0.0001 increase compared with baseline;
****, P  0.00001.
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this manner the responses of norepinephrine to glucagon
did not differ significantly among the three groups.
The degree of overlap among the three groups of sub-
jects was larger for the responses of plasma epinephrine to
glucagon than for the responses of norepinephrine (Fig. 2).
Median increments in plasma concentrations of epineph-
rine were 0.30 nmol/liter in patients with pheochromocy-
toma, comparedwith 0.19nmol/liter in those inwhom the
tumor was excluded, and 0.17 nmol/liter in the reference
group. Absolute increases in plasma epinephrine after glu-
cagon in the patientswith pheochromocytomawere larger
(P  0.05) than the increases in the reference group, but
not compared with the group in whom the tumor was
excluded. The relative increments in plasma epinephrine
concentrations after glucagon did not differ significantly
among patients with and without pheochromocytoma or
subjects in the reference group (Fig. 2).
In two patients with pheochromocytoma, the rise in
blood pressure necessitated the administration of phen-
tolamine.One other patientwith a history of hypertensive
paroxysms, but in whom pheochromocytoma was subse-
quently excluded, suffered a hypertensive crisis within the
first few minutes after glucagon. This was followed by a
long-lasting period of impaired vision in one eye, a serious
adverse event, but with full recovery after several months.
Diagnostic utility of the glucagon stimulation test
Irrespective of the various criteria used to define a pos-
itive test result, the diagnostic sensitivity of the glucagon
stimulation test remained less than 50% (Table 2). Values
for diagnostic specificity varied between 87 and 100%.
Thus, the corresponding positive predictive values ranged
between 86 and 100% with negative predictive values of
51% or less.
The highest diagnostic sensitivity of the glucagon test
(48%) was defined by increases in plasma concentrations
of norepinephrine after glucagon ofmore than 1.25 nmol/
liter (Table 2). The additional consideration of plasma
epinephrine responses to glucagon was of no value in in-
creasing diagnostic sensitivity, but instead led to a de-
crease in diagnostic specificity from 92 to 87%. Larger
than 3-fold increases in plasma concentrations of norepi-
nephrine after glucagon yielded the highest diagnostic
specificity of 100% with the corresponding maximum
positive predictive value; however, this definition of a pos-
itive test result was associated with a value for diagnostic
sensitivity of only 22%. Diagnostic accuracy associated
with the different diagnostic criteria ranged from 51%
(more than three times baseline plasmanorepinephrine) to
65% (increase in plasma norepinephrine of 1.25 nmol/
liter). Because of the near complete overlap in fold-in-
creases in plasma epinephrine among the three groups
(Fig. 2), there was no additional value in considering this
variable among the criteria for defining a positive gluca-
gon test result.
There were clear differences in responses to glucagon
between patients with VHL syndrome and MEN-2.
Among these two groups of patients with pheochromo-
cytoma, the glucagon test yielded negative test results ac-
cording to all four criteria in 20 of the 23 VHL patients
(diagnostic sensitivity 13%) compared with four of the
14 MEN-2 patients (diagnostic sensitivity  71%).
Diagnostic sensitivity did not improve when the anal-
ysiswas limited to those 15patientswhohadnormal base-
line plasma concentrations of norepinephrine and epi-
nephrine. Nine of these 15 patients showed normal
glucagon test results (i.e. false-negative results) according
to all four criteria, resulting in a diagnostic sensitivity of
40%. Excluding the six VHL patients from this subanaly-
sis yielded a diagnostic sensitivity of 66%.
Restricting the analysis to the 35 patients with pheo-
chromocytoma who had elevations of plasma normeta-
nephrine and/ormetanephrine that were not large enough
to unequivocally confirm the tumor (i.e. concentrations
higher than the upper reference limits but less then four
times the upper reference limit) also did not result in im-
proved diagnostic sensitivity. Glucagon test results were
normal (i.e. false-negative results) in 23 of these 35 pa-
tients according to all four predefined criteria, whereas in
12patients glucagon test resultswerepositive according to
at least three criteria. Thus, diagnostic sensitivity in this
TABLE 2. Sensitivities, specificities, and positive and negative predictive values for different parameters of plasma
norepinephrine and epinephrine at a cutoff level as established by the highest value in the reference group
Sensitivity Specificity
Positive
predictive value
Negative
predictive value
 Plasma norepinephrine (1.25 nmol/liter) 48% (31/64) 92% (35/38) 91% (31/34) 51% (35/68)
 Plasma norepinephrine (1.25 nmol/liter)
and/or  plasma epinephrine (1.46 nmol/liter)
48% (31/64) 87% (33/38) 86% (31/36) 50% (33/66)
Fold-increase over baseline norepinephrine
(2.03 times)
34% (22/64) 97% (37/38) 96% (22/23) 46% (37/81)
Fold-increase over baseline norepinephrine
(3.0 times)
22% (14/64) 100% (38/38) 100% (14/14) 43% (38/88)
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group was only 34%, but it increased to 63% after ex-
cluding the 16 VHL patients.
Expression of the glucagon receptor in tumors
from VHL and MEN-2 patients
In the subset of tumors from the sevenMEN-2 patients
and 11 VHL patients, mRNA expression for the glucagon
receptor was substantially higher (P  0.01) in tumors
fromMEN-2patients (median, 1,585; range, 169–10,960
relative units) than from the VHL patients (median, 25;
range, 0–2,957 relative units). Representative immuno-
histochemical stainings for tyrosine hydroxylase and the
glucagon receptor in single tumor specimens from one pa-
tient with MEN-2 and another with VHL syndrome are
shown in Fig. 3. Among the tumors from the six patients
with MEN-2 and the four patients with VHL syndrome,
all showed intense staining for tyrosine hydroxylase. All
tumors fromMEN-2 patients also showed a scattered pat-
tern of staining for the glucagon receptor, with 30 to 70%
of tyrosine hydroxylase-positive cells also showing stain-
ing for the glucagon receptor. In contrast, there was neg-
ligible specific staining for the glucagon receptor in ty-
rosine hydroxylase-positive cells of tumor specimens from
the four VHL patients.
Discussion
The results of this study clearly show that the glucagon test
used as a follow-up test has insufficient diagnostic sensi-
tivity to reliably exclude pheochromocytoma. Our anal-
ysis indicated that irrespective of the criteria used to define
a positive test result, the diagnosis would be missed in
more than 50% and up to 80% of patients suspected of
harboring the tumor. This applies in particular to those
patients for whom this test has been proposed to be most
useful, namely patients with normal plasma or urinary
catecholamines (11, 15).Ofmore relevance to current rec-
ommendations that initial diagnostic testing should in-
cludemeasurements of plasma freeorurinary fractionated
metanephrines (16), we also established that diagnostic
sensitivity of the glucagon test remains low when applied
to patients with borderline elevations of plasma meta-
nephrines that are of insufficient magnitude to unequiv-
ocally confirm pheochromocytoma.
As developed and described by Lawrence in 1965 (6),
use of the glucagon test to diagnose pheochromocytoma
initially depended on findings of excessive blood pressure
responses to glucagon compared with the blood pressure
response to a cold pressor test. Use of plasma catechol-
amine responses as diagnostic end-points for the glucagon
test followed improvements in assay methodologies that
enabled measurements of catecholamines in plasma (7,
15). Several subsequent reports indicated that the gluca-
gon test can be particularly useful for establishing the di-
agnosis of pheochromocytoma in patients where other
biochemical test results produce inconclusive results (10,
11, 17). The largest of these previously published studies
was by Grossman et al. (11), who reported on 31 patients
with pheochromocytoma and 72 symptomatic patients in
whom the tumor had been excluded. Sensitivity of the test
was reported at 81% and specificity at 100%. The high
diagnostic specificity indicated potential utility of the test
for conclusive confirmation of pheochromocytoma.
Optimism about the glucagon test has, however, been
temperedbyother reports indicating several shortcomings
(17–20). Notably, there has been disagreement about
whether iv glucagon can produce increases in plasma cat-
echolamines in the absence of a pheochromocytoma. Al-
though some investigators have indicated that glucagon is
normally without affect on plasma concentrations of nor-
epinephrine and epinephrine (15), others have reported
small increases largely limited to epinephrine (9–11), and
still others reported substantial increases in both norepi-
nephrine and epinephrine (19).
Thepresent studyof theglucagon test—todate the largest
of its kind and the first to include a reference population—
clearly establishes that iv glucagon produces significant in-
creases of both plasma norepinephrine and epinephrine, ir-
respective of the presence of a pheochromocytoma. In all
patients without pheochromocytoma, including subjects
of the reference group, the absolute increments of plasma
FIG. 3. Immunohistochemical staining of tyrosine hydroxylase (TH;
panels A and C) and of the glucagon receptor (GR; panels B and D) in
representative samples of pheochromocytomas from patients with
MEN-2 (A and B) and VHL syndrome (C and D).
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epinephrine were of similar magnitude to those of plasma
norepinephrine. More importantly, both the relative (i.e.
fold-increases) and absolute increments of plasma epi-
nephrine did not differ among subjects with and without
pheochromocytoma. Thus, consideration of glucagon-
evoked increases in plasma epinephrine, in addition to
norepinephrine, provides no additional utility in improv-
ing the diagnostic accuracy of the test beyond consider-
ation of norepinephrine responses alone. In fact, the ad-
ditional consideration of epinephrine responses leads to
decreased diagnostic specificity.
Our findings that relative increments (i.e. fold-increases)
inplasmanorepinephrinealsodidnotdifferbetweenpatients
with and without pheochromocytoma indicate a further
short-coming in the usual use of glucagon-induced fold
increases inplasmanorepinephrine todefine apositive test
result. Consequently, use of absolute increments to de-
fine a positive test result, as determined by the maxi-
mum increment of plasma norepinephrine in our refer-
ence population, provided higher diagnostic sensitivity
than use of fold-increases.
The present findings of significant responses of norepi-
nephrine and epinephrine to glucagon that were indepen-
dent of the presence of a pheochromocytoma are consis-
tent with other findings showing that glucagon can evoke
catecholamine release from both isolated pheochromocy-
toma tumor cells and adrenal medullary chromaffin cells
(21). This evoked release appears dependent on the pres-
ence of the glucagon receptor (22). As we further show
here, differences in the expressionof the glucagon receptor
in pheochromocytomas likely explain the variable cate-
cholamine responses to glucagon and the correspondingly
poor diagnostic sensitivity of the glucagon test among pa-
tientswith pheochromocytoma.More specifically, the no-
tably higher rate of false-negative responses to glucagon in
VHL patients (87%) compared with MEN-2 patients
(29%) can be explained by the relative lack of expression
of the glucagon receptor in tumors from VHL patients.
Although sensitivity of the glucagon test is insufficient
for reliable exclusionofpheochromocytoma, specificityof
the test is excellent, a finding in agreement with the results
of a previous study (11). It might be argued that the high
diagnostic specificity of the glucagon test makes it useful
as a secondary test to confirm pheochromocytoma in pa-
tients in whom initial biochemical tests yield equivocal
results. However, it must also be considered that an un-
equivocal diagnosis of pheochromocytoma using the glu-
cagon test could only be reached in at most one third of
patients with the tumor; in all other patients with and
without tumors the diagnosiswould remain unclear,mak-
ing the test unacceptable for clinical practice. To be effec-
tive, follow-up tests should ideally have both higher diag-
nostic sensitivity and specificity than the initial screening
test. As previously described, the clonidine suppression
test,when combinedwithmeasurements of normetaneph-
rine, has nearly 100% sensitivity and specificity, making
this an excellent follow-up test (23). Nevertheless, even
before that particular test is implemented, due consider-
ation should also be given to other simpler to implement
biochemical tests that can be performed after excluding
possible causes of false-positive test results (24).
Finally, as reviewed elsewhere (25), use of the glucagon
test is not without risk. This was illustrated in the present
study by severe hypertensive reactions in three patients,
including one patient who did not harbor a pheochromo-
cytoma. Importantly, in that latter patient, the hyperten-
sive crisis was associated with a severe adverse event, in-
volving impaired vision in one eye that only slowly
resolved over severalmonths. Thus, the risks of the test are
not insubstantial and should be balanced against any ben-
efits for diagnosis of suspected pheochromocytomas.
In summary, the glucagon stimulation test offers insuf-
ficient diagnostic sensitivity for reliable exclusion of pheo-
chromocytoma or confirmation of disease in all patients
with the tumor. Taking this into account, along with ad-
vances in other biochemical testing strategies and the risk
of hypertensive complications, we conclude that there is
no justification for this test in routine clinical practice.
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